#earlybreastcancer resultados da pesquisa

How important is overall survival in #EarlyBreastCancer? Overall survival plays a central role in shaping treatment decisions and defining meaningful outcomes in curative settings. Follow us for more on #ESMOBreast26.

For patients with #EarlyBreastCancer, long-term #RiskOfRecurrence is closely tied to nodal status: 20-year distant recurrence risk is 𝟮𝟮% with no positive nodes, 𝟯𝟭% with 1–3 nodes, and 𝟱𝟮% with 4–9 nodes. How does this affect your treatment planning?

Despite advances in therapy, patients with node-positive HR+/HER2– #EarlyBreastCancer still face a high #RiskOfRecurrence. Dr @Rodrosb discusses his perspective on how to fine-tune risk calculations, including emerging biomarkers and gene expression profiling.

Did you know that most cases of #EarlyBreastCancer recurrence occur within the first 5 years after diagnosis? This critical window may offer an opportunity to guide individualized therapy decisions for patients.

🩺 Helping patients with HR+/HER2- #EBC understand their recurrence risk is key. Dr. O'Shaughnessy shares her approach to setting expectations & quantifying risk of recurrence. Watch the full video & access more resources here: e.lilly/4tYR2VT #EarlyBreastCancer #BCSM

Effective, patient-centred communication improves patients’ understanding of their #RiskOfRecurrence and management options. @ProfMarcThill provides a clinician’s perspective on how to improve communication with patients who have HR+/HER2- #EarlyBreastCancer

🔗doi.org/10.1007/s00508… Authored by leading #ABCSG investigators, this publication provides orientation in a changing therapeutic landscape and supports informed treatment decisions in clinical practice. #EarlyBreastCancer #Oncology #CancerResearch #AdjuvantTherapy

Have you considered a molecular approach to assessing #RiskOfRecurrence? ctDNA detection can be used in the clinic to improve patient prognosis and monitor response to therapy in patients with #EarlyBreastCancer.

This is important data we can use in the clinic. Extending ET in premenopausal patients with node-positive eBC after 5 years of LHRHa treatment was associated with a clinically meaningful reduction in both invasive and distant breast cancer recurrences. #EarlyBreastCancer

Did you know that original nodal status and tumor diameter are remarkably strong determinants of #RiskOfRecurrence among patients with HR+ #EarlyBreastCancer. Follow us for more Breast Cancer Insights.

(2/2) 👉In carefully selected luminal, low–tumor burden patients, RFA may represent a minimally invasive alternative to partial mastectomy #EarlyBreastCancer #MinimallyInvasive #BreastCancerCare

In HR+/HER2– #EarlyBreastCancer, assessing #RiskOfRecurrence requires more than one approach. Dr @Rodrosb explains how clinical features, genomic tools, biomarkers, and multidisciplinary care can refine risk assessment and guide management.

📷Participate in the full Early Breast Cancer quiz here: bit.ly/EBC_ONCO_IQ_X 47yr lady with stage II TNBC gets neoadjuvant Pembrolizumab + chemo(KEYNOTE-522). Surgery shows pCR. What is the next step? #EarlyBreastCancer #BreastCancer #MedTwitter #OncTwitter #MedEd #ONCOIQ

Neocarhp finally out! There is a potential to de escalate chemo in patients with her2 pos early stage breast cancer! #EarlyBreastCancer #HER2BreastCancer #OncologyUpdates #PrecisionOncology

APBCS 2026 - Key Considerations Before And During Immunotherapy And Chemotherapy Treatments In Early-Stage TNBC @APBCSUMMIT @APBCS oncodaily.com/voices/apbcs-2… #APBCS2026 #TNBC #EarlyBreastCancer #Cancer #Medicine #Health #Oncology #OncoDaily #MedX #MedNews #MedEd

Key considerations before and during immunotherapy and chemotherapy in early-stage TNBC—covering patient selection, sequencing, and treatment optimization. Sat, 8 Feb 2026 | 11:30–12:45 MYT Register: apbcs.org/registration/ #APBCS2026 #TNBC #EarlyBreastCancer #Immunotherapy

It's concerning yet important to highlight the long-term recurrence risk in HR+, HER2− #EarlyBreastCancer. With advancements in personalized and targeted therapies, is there a push towards genomic profiling to better predict individual risks? Contextualizing research outcomes

Management of HR+, HER2− #EarlyBreastCancer continues to evolve, but long-term recurrence remains a challenge for many patients – even after 20 years.¹,² Recognizing those at risk can improve outcomes.¹,² Follow for more.

Shaping Tomorrow: Redefining Risk in HR+ HER2- eBC A forward-looking symposium exploring how evolving evidence is redefining risk assessment and treatment decisions in early breast cancer. To register: apbcs.org/registration/ #APBCS2026 #EarlyBreastCancer #HRPositive

• Top 6 Q&A on adjuvant CDK4/6 in early breast cancer • Practice- and debate-relevant • Quick revision in under 30 seconds #EarlyBreastCancer #CDK46 #Oncology #NATALEE #MVOnco

• Top 6 Q&A on adjuvant CDK4/6 in early breast cancer • Practice- and debate-relevant • Quick revision in under 30 seconds #EarlyBreastCancer #CDK46 #Oncology #NATALEE #MVOnco

Join us for a virtual treatment expert panel with a focus on #EarlyBreastCancer. This event is part of the #BreastCancerInYoungAdults forum series for patients, survivors, and loved ones. 🗓️Wed, Sept 10 | 6:30 – 7:45 pm ET A panel of medical, surgical, and radiation oncologists

Pivotal Data on Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer - Sibylle Loibl oncodaily.com/voices/sibylle… #DESTINYBreast05 #GBG #EarlyBreastCancer #SABCS2025 #Cancer #Medicine #Health #Oncology #OncoDaily #MedX #MedNews #MedEd

Ann Partridge, MD, MPH (@AnnPartridgeMD) at the #SABCS23 Year in Review, where she did an excellent job highlighting the key findings in #EarlyBreastCancer from the past year.

APBCS 2026 - Key Considerations Before And During Immunotherapy And Chemotherapy Treatments In Early-Stage TNBC @APBCSUMMIT @APBCS oncodaily.com/voices/apbcs-2… #APBCS2026 #TNBC #EarlyBreastCancer #Cancer #Medicine #Health #Oncology #OncoDaily #MedX #MedNews #MedEd

Congrats to Dr. Jennifer Ligibel and colleagues on this recently published secondary analysis of a phase III randomized double-blind trial in #EarlyBreastCancer on the effect of #metformin vs placebo on New Primary Cancers pubmed.ncbi.nlm.nih.gov/37695982/

Novartis Provides Longer-Term Data from P-III (NATALEE) Trial of Kisqali (Ribociclib) to Treat Early Breast Cancer pharmashots.com/20279/novartis… #novartis #kisqali #earlybreastcancer #clinicaltrial

Risk of recurrence is essential to inform clinical decisions in management of #EarlyBreastCancer.¹,² How can all patients at #RiskOfRecurrence be identified to improve outcomes? Watch the video to find out more: x.com/LillyOncInt/st…

Sharing Progress in Cancer Care #SPCC & @EliLillyandCo are collaborating and seeking grant proposals in support of improving 📈 the care of #EarlyBreastCancer (EBC) patients in Europe 🇪🇺 🔗spcc.net/en/projects/im…

Dr Vishnu Kurpad from @shankaracancer, presented on ‘Early Breast Cancer & SLNB’ at the Prof. B. Hanumaiah Memorial National Continuing Surgical Education Program '24 on November 11th. His talk emphasized early detection and SLNB's role in treatment. #EarlyBreastCancer #SLNB

Rachel Freedman, MD (@DrRFreedman) discusses CDK4/6 therapy for patients with #EarlyBreastCancer medpagetoday.com/reading-room/a…

Day1. Esmo Asia conference 2023 Accessible and affordable healthcare . Newer drugs and molecular targets how to cope up . Presented Data from India #earlyBreastCancer #SuntecCitySingapore convention centre .courtesy Dr Reddy’s #EsmoAsia2023 Lesser stall and less attendees

Join #EarlyBreastCancer experts Laura S. Dominici, MD, FACS (@dr_laurad), Albert Diehl, MD, & Jane L. Meisel, MD (@jane_meisel) on 3/21 at 7 PM EDT during #SSO2024 for a #BreastCancer Live #MedEd Symposium. Sign up now to join us there! bit.ly/24EBCT #MedEd #MedTwitter

The highest risk of first recurrence in patients with #EarlyBreastCancer occurs within the first five years after diagnosis. Could this critical period serve as a window of opportunity in guiding more objective and individualised therapy decisions in the future?

Day 2. Esmo Asia conference 2023 Accessible and affordable healthcare . Newer drugs and molecular targets how to cope up . Presented Data from India #earlyBreastCancer #SuntecCitySingapore convention #ESMOAsia23 #europeanSocietyMedicalOncology Lesser stall and less attendees

#ESMOBreast23 📍Berlin on your mind? Come to the In-Person and Virtual Satellite Symposium on #EarlyBreastCancer to learn more about adjuvant targeted treatment strategies #AnswersinCMELive #GetYourAnswersinCME buff.ly/3p9iinV

Have you explored molecular methods for assessing #RiskOfRecurrence? For example, analysis of circulating tumor DNA may be used to predict the risk of recurrence in patients with #EarlyBreastCancer.¹,²

Many #EarlyBreastCancer survivors live with persistent fear of recurrence, affecting their mental health and decisions. This underscores the need for strong risk communication and ongoing psychosocial support.

High BMI can be an underrecognized factor contributing to poor prognosis in patients with #EarlyBreastCancer. As risk stratification tools evolve, how should body composition be integrated into long-term care strategies and intervention planning?

Day 3Esmo Asia conference 2023 Accessible and affordable healthcareNewer drugs and molecular targets how to cope up . Presented Data from India #earlyBreastCancer #SuntecCitySingapore convention centre . #europeanSocietyMedicalOncology #EsmoAsia2023 Lesser stall less attendees